Mylan’s second-ranked exec allegedly took an active role in a vast and “sinister” price-fixing conspiracy among global makers of generic pills.
Mylan’s second-ranked executive took an active role in a vast and “sinister” price-fixing conspiracy among global makers of generic pills that kept prices of the medications artificially high, dozens of states alleged in a new complaint.
The multiyear civil investigation by state attorneys general has now reached the highest echelons of the drugmakers, naming Rajiv Malik, Mylan’s president and executive director, as one of the first two executives to be targeted in the case. Other managers in the industry are under investigation, according to Connecticut officials.
